- Home
- LOMA vs CLDX Comparison
LOMA vs CLDX Comparison
Compare LOMA & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOMA
- CLDX
- Stock Information
- Founded
- LOMA 1926
- CLDX N/A
- Country
- LOMA Argentina
- CLDX United States
- Employees
- LOMA N/A
- CLDX 186
- Industry
- LOMA Building Materials
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LOMA Industrials
- CLDX Health Care
- Exchange
- LOMA Nasdaq
- CLDX Nasdaq
- Market Cap
- LOMA 1.3B
- CLDX 1.4B
- IPO Year
- LOMA 2017
- CLDX 2008
- Fundamental
- Price
- LOMA $10.18
- CLDX $22.46
- Analyst Decision
- LOMA Strong Buy
- CLDX Strong Buy
- Analyst Count
- LOMA 2
- CLDX 9
- Target Price
- LOMA $15.00
- CLDX $46.13
- AVG Volume (30 Days)
- LOMA 491.3K
- CLDX 1.3M
- Earning Date
- LOMA 08-07-2025
- CLDX 08-07-2025
- Dividend Yield
- LOMA N/A
- CLDX N/A
- EPS Growth
- LOMA N/A
- CLDX N/A
- EPS
- LOMA 0.37
- CLDX N/A
- Revenue
- LOMA $559,741,122.00
- CLDX $5,790,000.00
- Revenue This Year
- LOMA $22.92
- CLDX N/A
- Revenue Next Year
- LOMA $25.84
- CLDX N/A
- P/E Ratio
- LOMA $27.67
- CLDX N/A
- Revenue Growth
- LOMA N/A
- CLDX N/A
- 52 Week Low
- LOMA $6.76
- CLDX $14.40
- 52 Week High
- LOMA $14.17
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- LOMA 36.10
- CLDX 49.39
- Support Level
- LOMA $11.00
- CLDX $20.37
- Resistance Level
- LOMA $10.87
- CLDX $25.65
- Average True Range (ATR)
- LOMA 0.50
- CLDX 1.56
- MACD
- LOMA -0.16
- CLDX -0.12
- Stochastic Oscillator
- LOMA 4.37
- CLDX 45.14
About LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.